Welcome to the International Neuromodulation Society

2017 INS Congress Announcement

Breaking News

 

Company Receives CE Mark Approval for Neurostimulation Device Targeting Back Pain

May 25, 2016 - Mainstay Medical International plc announced it has received CE mark approval for its implantable neurostimulation system to treat disabling chronic low back pain. The company plans a commercial launch in Germany. These plans include conducting a post-market clinical data follow up. A clinical trial in the U.S. may follow. (Business Wire)

Texas Company to Work With Pittsburgh Researchers on A Bladder-Control Implant for Spine-Injured Patients

May 24, 2016 - InCube Labs of San Antonio, TX has been awarded a $10 million subcontract, part of a U.S. Department of Defense contract, to work with the University of Pittsburgh on developing an implant that could improve or restore bladder function in patients who have suffered spinal cord injuries. (My SA)

TV Show Publicizes Montreal Clinical Trial of Non-invasive Neurostimulation for Gait Rehabilitation

May 23, 2016 - A television news show reports on a clinical trial into a non-invasive neurostimulation device that is applied on the tongue and is being investigated to augment physical therapy for gait in patients who have multiple sclerosis or suffered a traumatic brain injury. The news segment features a former U.S. talk show host and military veteran, Montel Williams. He has multiple sclerosis and became involved with the device's commercialization after having been one of its early study subjects. (CTV Montreal)

Article: Vagus Nerve Stimulation Offers Potential Promise in Addressing Obesity

May 21, 2016 - An article published in the United Arab Emirates describes hopes of being able to address obesity through vagus nerve stimulation, calling the concept "tweaking the behaviour of specific organs by remote control." (The National)

Academic Team Will Study Non-Invasive Brain Stimulation and Alzheimer's Disease

May 21, 2016 - The Fremont (Nebraska) Area Alzheimer’s Collaborative presented early stage research funding to Alzheimer's disease researchers at the University of Nebraska Medical Center. The researchers plan to use non-invasive brain stimulation to explore the role of the hippocampus in memory and cognitive function. (Fremont Tribune)

Young Girl Resuscitated After Almost Drowning Will Undergo Deep Brain Stimulation

May 20, 2016 - An article published in South Africa tells the story of a 6-year-old who will undergo deep brain stimulation for a movement disorder subsequent to a near-drowning at age 2. (Independent Online)

Device Company Announces Launch of MRI-Compatible Spinal Cord Stimulation System

May 19, 2016 - Boston Scientific Corporation announced it received FDA approval of its MRI-safe spinal cord stimulation system, which it will launch during the World Institute of Pain annual meeting, taking place May 20 - 23, 2016. The company said the FDA cleared the system for full-body, 1.5 Tesla MRI scans, and that it is designed to deliver multiple waveforms. (Mass Device)

Optogenetics Studies Move Beyond Retinal Applications to Potentially Address Pain or Other Conditions

May 19, 2016 - A news feature describes the start of a safety trial that is investigating an optogenetic intervention to potentially restore some vision to patients who have retinitis pigmentosa, through inducing retinal ganglion cells to produce light-sensitive proteins. Meanwhile, the article notes that preclinical work has begun to potentially use optogenetics to treat pain, via a light-sensitive patch worn on the skin. Other potential indications being considered for an optogenetic intervention include hearing, function of vocal cords, bladder function, and Parkinson's disease and other brain disorders. (Nature)

Twins Said to Be the First in Colorado to Receive Deep Brain Stimulation for OCD

May 18, 2016 - International Neuromodulation Society member David VanSickle, MD, PhD, was interviewed in a television newscast about treating what were said to be the first patients in Colorado to receive deep brain stimulation for obsessive compulsive disorder. He said he worked to convince the insurance company to cover the operation for a pair of young adult twin girls who were severely disabled by the condition. The patients said their symptoms have lessened since the treatment. Their story was also featured as a cover article in the Spring 2016 issue of the Littleton Adventist Hospital health magazine. In that article, Dr. VanSickle said the procedure has become "more consistent, faster, much less expensive . . . yet it's highly underutilized as a therapy." (9News.com)

Study: Spinal Cord Stimulation Helped Tetraplegic Patients Regain Some Use of Their Hands

May 17, 2016 - A publication reports that cervical spinal cord stimulation and motor training in two patients who had been paralyzed for more than 18 months following severe spinal cord injury allowed them to gain the ability to grasp and hold small objects. By the end of the study, the patients retained some improvement even after the stimulator was turned off. (National Institute of Biomedical Imaging and Bioengineering)

Physician Explains Interest in Neurostimulation for Cluster Headache

May 16, 2016 - A local T.V. segment focuses on a cluster headache patient in the Washington, D.C. area whose doctor is thinking of enrolling him in a clinical trial of sphenopalatine ganglion stimulation. (WUSA)

Researchers Model Effectiveness and Costs of Non-invasive Vagus Nerve Stimulation for Cluster Headache

May 16, 2016 - The company electroCore has issued a press release about research published last month showing that non-invasive vagus nerve stimulation for cluster headache is effective and cost-effective, according to scenarios modeled from a German health economy perspective. (PRLog)

Review Ponders Vagus Nerve Stimulation for Heart Failure

May 13, 2016 - A review of the INOVATE-HF controlled clinical trial of vagus nerve stimulation concludes that despite intriguing improvements in secondary endpoints, the approach "has to go back to the drawing board." The reviewer cite the lack of significant differences in the main endpoint of death or worsening heart failure, and the occurrence of device complications in almost one out of 10 patients. (NEJM Journal Watch)

Paper Calls Vagus Nerve Stimulation in Drug-Resistant Epilepsy a "Viable Alternative"

May 12, 2016 - A retrospective study of 20 patients with drug-resistant epilepsy who received a vagus nerve stimulation implant between 2001 and 2010 at two institutions in Turkey calls the treatment a "viable alternative" for patients who have drug-resistant epilepsy or who either could not have epilepsy surgery or did not benefit from it. (Univadis)

Review Looks at Incidence and Management of Postdural Puncture Headache After Spinal Cord Stimulator Implantation

May 12, 2016 - International Neuromodulation Society member Thomas Simopoulos, MD and colleagues found an incidence of 0.81% of postdural puncture headache following implantation of 745 spinal cord stimulation leads at a large academic medical center from 2002 to 2014. The six cases they reviewed all occurred before imaging via contralateral oblique fluoroscopic view entered the practice in 2011. They conclude that with meticulous aseptic technique, managing the puncture with epidural blood patch is safe and efficacious even in the presence of hardware. (Neuromodulation: Technology at the Neural Interface)

Electroceutical Startup Raises $8 Million

May 12, 2016 - An article reports that Silicon Valley startup NeuSpera Medical has raised $8 million in Series A financing for its injectable neuromodulation technology. The company was founded in 2014 as Vivonda Medical, and is targeting applications in electroceuticals, which the article calls "a futuristic field that already has substantial strategic interest." (Fierce Medical Devices)

Company Targeting Gastro-esophogeal Reflux Disease Raises $25 Million

May 12, 2016 - EndoStim, Inc. completed a Series D financing round of $25 million that will go in part toward clinical trials of its neurostimulation therapy for acid reflux. (PE Hub Network)

Company Announces Fast-Track Designation from the FDA

May 11, 2016 - Lungpacer Medical received approval to use the FDA expedited access pathway for its diaphragm pacing system. The system provides temporary transcatheter stimulation of the phrenic nerve to aid weaning patients from mechanical ventilation. (Mass Device)

Device Maker Releases First-Quarter Financial Report

May 11, 2016 - Nuvectra Corporation announced first-quarter financial results. The company's total revenue was $2.1 million, up 76% from the same quarter one year ago. Operating expenses were $8.1 million, a 42% increase from one year ago. The company completed its spin-out March 14. The company established a term loan agreement in March. Overall its net loss for the quarter was $0.70 per share, compared to $0.54 per share in the first quarter of 2015. The first commercial implants began in April for its first product, a spinal cord stimulation system. (Nasdaq)

Clinicians Present Data on Neuromodulation Device Outcomes for Bladder Indications

May 10, 2016 - A summary from a presentation at the American Urological Association's annual meeting reported data from a 5-year projection of comparative costs of percutaneous tribal nerve stimulation (PTNS) versus medical management. The data developed in London, U.K. led to a conclusion that PTNS has a greater overall cost, but is more effective than single or dual drug therapy and therefore provides reasonable value in treating overactive bladder. Another summary from the meeting concerned data from a single Cleveland, Ohio institution where 1,033 sacral neuromodulation procedures had an overall infection rate of 1.8%. In addition, the authors found the rate varied by primary indication. Non-obstructive urinary retention had higher rates, although the reason for this unexpected finding was not explored. (Uro Today)

Company's Pain-Relief Device Sales Were Higher Than Anticipated

May 10, 2016 - First-quarter sales for Nevro Corp. were higher than analysts' forecasts and the company raised its guidance about 2016 anticipated earnings. The company's spinal cord stimulation system received FDA approval last May. (Fierce Medical Devices)

Columnist: Are Non-drug Therapies Gaining Favor?

May 10, 2016 - A column discusses the total lifetime costs of drug therapies compared to neuromodulation therapy and mentions a recent article http://onlinelibrary.wiley.com/doi/10.1111/ner.12389/abstract in Neuromodulation: Technology at the Neural Interface. (Neurotech Business Report)

Researchers Pursue Potential Therapies Based on Vagus Nerve Stimulation

May 10, 2016 - An article describes some research in the European Union into advanced vagus nerve stimulation for obesity or inflammation. (Horizon)

Urologists Hear Analysis of Sacral Neuromodulation Study Data

May 9, 2016 - A physician who presented clinical research data about sacral neuromodulation at the annual meeting of the American Urological Association said the findings suggest that physicians should probably move to third-line therapies more quickly, after patients have failed just a few medications. The study of 272 subjects was a retrospective sub-analysis of a 5-year prospective study into the use of tined leads. (Urology Times)

Pilot Study Will Investigate Hypoglossal Nerve Stimulation in Certain Pediatric Patients Who Have Sleep Apnea

May 9, 2010 - A pilot clinical trial https://clinicaltrials.gov/ct2/show/NCT02344108?term=hypoglossal+nerve+sleep+apnea+down+syndrome&rank=1 of hypoglossal nerve stimulation for sleep apnea has started in pediatric patients with Down syndrome who cannot tolerate wearing continuous positive airway pressure masks at night. (Medical Xpress)

Company Plans a Stock Offering to Shareholders

May 9, 2016 - Second Sight Medical Products, Inc. is offering its shareholders subscription rights to purchase a proportionate amount of additional stock at $4.25 per share or 85% of the Nasdaq closing price by May 31, 2016. The proceeds will be used to fund operations and research, such as development of a cortical visual prosthesis as well as continuing a post-market clinical study of the company's retinal prosthetic for age-related macular degeneration. (Yahoo Finance)

Company Targeting Urogenital Indications Announces Patents

May 9, 2016 - Axonics Modulation Technologies, Inc. announced it received six U.S. patents relating to implantable neuromodulation technology and recharging systems in the past 12 months. The company said its initial clinical application is sacral neuromodulation to treat urinary and fecal dysfunction, which it said affects more than 100 million adults in the U.S. and Europe. (Yahoo Finance)

Review: Further Investigation of Potential Neuromodulation Therapies is Warranted in Memory-and-Learning Disorders

May 2016 - A review summarizes cortical-subcortical brain circuits that are important in learning and memory disorders such as Alzheimer's disease. The paper discusses mechanisms such as firing patterns, neural plasticity and neurogenesis, and goes over the current potential neurostimulation targets in those circuits, in addition to other possible therapies. (Journal of Neuroscience)

Paper Examines Importance of Total Charge Delivery Over Time in Spinal Cord Stimulation

May 6, 2016 - International Neuromodulation Society members Jonathan Miller, MD, Sam Eldabe, MD, Eric Buchser, MD, Lisa Johanek, PhD, Yun Guan, MD, PhD, and Bengt Linderoth MD, PhD published an article about spinal cord stimulation (SCS) that considers the overall rate of charge delivery, in addition to the the programming parameters of pulse width, amplitude, and frequency. The authors say SCS parameters that deliver different amounts of energy through different duty cycles may exert distinct therapeutic effects, such as little or no sensory perception of the stimulation. They say considering total charge delivery over time is a concept that applies to both conventional. tonic SCS and newer forms such as high frequency and burst stimulation. (Neuromodulation: Technology at the Neural Interface)

Pain Publication Covers International Neuromodulation Society Journal Article

May 6, 2016 - Coverage of an article about spinal cord stimulation and the emotional aspect of pain in Neuromodulation: Technology at the Neural Interface includes a comment from International Neuromodulation Society member Ali Rezai, MD. He said, “Being able to modulate the connections between the brain areas involved in emotions and those linked to sensations may be an important mechanism involved in pain relief linked to spinal cord stimulation.” (National Pain Report)

International Neuromodulation Society Member Investigates Potential New Brain Stimulation Target for Bipolar Disorder

May 5, 2016 - International Neuromodulation Society member Jennifer Sweet, MD, is beginning a clinical trial of deep brain stimulation (DBS) in bipolar disorder. In the first phase, in diffusion-weighted imaging of neural connectivity, medication-resistant patients will be compared to patients who respond to medication and to healthy controls. In the second phase, six medication-resistant patients who have abnormal connectivity will be recruited for a randomized, double-blinded pilot study of DBS targeting the rostral dorsal cingulum bundle, which plays a role in cognitive control. (University Hospitals Case Medical Center)

Meta-Analysis Summarizes Studies Comparing Deep Brain Stimulation Targets in Parkinson's Disease

May 4, 2016 - A review analyzes 16 studies that compare deep brain stimulation (DBS) to the subthalamic nucleus (STN) or the globus pallidus internus (GPi) in Parkinson's disease. The results show STN-DBS was more effective in reducing medication usage and GPi-DBS was more effective in resulting in a higher quality-of-life score. (Scientific Reports)

Computer Simulation Suggests Mechanisms Underlying Paresthesia-Free High-Frequency Spinal Cord Stimulation

May 4, 2016 - International Neuromodulation Society members Jeffrey Arle, MD, PhD, and Jay Shils, PhD, and colleagues have modeled high-frequency stimulation of dorsal column axons. According to their simulation, high-frequency, paresthesia-free stimulation leads to action potential blockade as hypothesized, preferentially occurring in larger diameter fibers, with recruitment of smaller and medium fibers. The effects arise from ion channel gate and virtual anode dynamics. (Neuromodulation: Technology at the Neural Interface)

Ongoing Clinical Trial of Deep Brain Stimulation in Alzheimer's Disease Explained

May 4, 2016 - A clinician involved in a study of deep brain stimulation in Alzheimer's disease was interviewed about the ongoing 10-person study to evaluate electrical stimulation of white matter in the ventral capsule of the frontal lobes, a region important in executive function and decision-making. (Medscape Multispecialty)

Review: Eligibility for Deep Brain Stimulation in Movement Disorders

May 3, 2016 - International Neuromodulation Society member Christopher Honey, MD, DPhil, and colleagues, published a review on currently available guidance about patient eligibility for deep brain stimulation in Parkinson's disease, tremor, and dystonia. (Canadian Journal of Neurological Sciences)

British TV Documentary Shows Tremor Relief from Deep Brain Stimulation

May 3, 2016 - The channel ITV will run a documentary of a man whose tremors were treated with deep brain stimulation. The show is part of the series "What Would Be Your Miracle?" about inspirational medical interventions. (Exeter Express & Echo)

Former Canadian Radio Host Appears in a Documentary about Deep Brain Stimulation for Parkinson's Disease

May 3, 2016 - A former radio announcer with Parkinson's disease is the subject of a documentary about his deep brain stimulation surgery. The film, "The Voice," is debuting at an international documentary film festival in Canada. (CBC News)

Neurostimulator Company Raises More Money in an Over-allotment Offering

May 3, 2016 - Helius Medical Technologies raised an additional $857,083 in an over-allotment to its latest offering, bringing the total to $8.1 million. The company said the proceeds will help fund completion of a clinical registry trial of its portable neuromodulation stimulator to evaluate treating traumatic brain injury, prior to seeking 510(k) clearance from the FDA. The company plans to also pursue indications in multiple sclerosis and stroke. (Mass Device)

Company Raises Capital to Commercialize Obesity-Treatment Neurostimulator

May 3, 2016 - EnteroMedics closed a third tranche in a $25 million offering, bringing in $6.3 million. The company is commercializing an implantable vagus nerve stimulator for obesity treatment. (Mass Device)

Device to Potentially Address Peripheral Nerve Pain Moves Forward in Competition

May 3, 2016 - Bioness, Inc. announced its implantable neurostimulator for peripheral neuropathic pain is a finalist for the 2016 Medical Device Excellence Awards. Results of the competition will be announced in June. (PR Newswire)

Columnist Sees Promise in April Developments in the Neurotechnology Industry

April 2016 - A column by an industry observer says that following St. Jude Medical's acquisition by Abott, other large healthcare firms may take greater interest in entering the neurotech arena. The column adds that proposed U.S. legislation, if passed, would require Medicare to automatically cover newly approved medical devices. Finally, the column notes the FDA is moving toward expediting access to market by considering lowering classification, from class III to class II, of cranial electrical stimulation systems for some indications. (Neurotech Business Reports)

Review Evaluates Evidence Base for Burst Stimulation

May 3, 2016 - A review of five published studies of burst spinal cord stimulation (SCS), involving 117 chronic pain patients, evaluates the evidence base and concludes that further study should use a standardized design, a large sample of patients who have not previously had SCS, and entail long-term follow-up. However, the study notes that new mechanisms may be at play in this stimulation mode, according to animal studies, and says, "understanding other potential spinal inhibitory mechanisms may lead to enhanced analgesia during burst stimulation." (Neuromodulation: Technology at the Neural Interface)

Editorial Considers Tailoring of Deep Brain Stimulation in Depression

May 2, 2016 - Commenting on a recent study into deep brain stimulation (DBS) for treatment-resistant depression, a psychiatrist notes that symptom improvement in the blinded study was not a placebo effect, and dosage adjustment led to better results. He adds that electrode placement may also be reconsidered as the potential intervention evolves, saying, "DBS is most likely to become a viable choice for highly refractory major depression when electrode location is matched to individual pathophysiology as indicated by functional neuroimaging." (NEJM Journal Watch)

Review Recounts History of Deep Brain Stimulation

April 29, 2016 - A review looks at the development of brain neuromodulation techniques and the current state of the art, including new research into stimulation using ultrasound, micro-scale magnetic fields and optogenetics. (Neuroscientist)

Researchers Report Non-invasive Brain Stimulation Led to More Cortical Excitability and Higher Pain Thresholds

May 2, 2016 - Researchers report a more-robust non-invasive brain stimulation method that increases cortical excitability and may help in devising interventions that raise the pain threshold for patients suffering from chronic pain. They used two electrodes on one side of the head and ran a constant low-intensity current between the electrodes for 10 minutes. Compared to previous studies that only used a single site for transcranial direct current stimulation (tDCS), this method, unihemispheric dual site tDCS, led to more-pronounced and more durable cortical excitation that lasted 24 hours, they report. Further tests showed that participants had an increased pain threshold. (Health Canal)

Neuromodulation Company is Acquired by Healthcare Giant

April 28, 2016 - Abbott is acquiring St. Jude Medical, Inc. for $25 billion. The deal provides a broader cardiovascular portfolio and also confers "a leading position in the high-growth neuromodulation market," it was reported today. Abbott, which has product lines in cardiovascular, diabetes, and vision care, will assume or refinance St. Jude's net debt of approximately $5.7 billion. (Street Insider)

Researchers Explore Non-Invasive Brain Stimulation in Alzheimer's Disease

April 27, 2016 - A pilot study in the Journal of Alzhemier's Disease explored, in 18 patients with mild, moderate, or severe Alzhemier's disease, a potential alternative brain-stimulation method to restore mental function. The researchers reported that there were temporary improvements in thinking skills and memory after six sessions of exposure to sound pulses at 40-hertz. This gamma wave rhythm has been shown to be a fundamental frequency of a healthy brain. The study builds on 2013 findings showing that vibrations delivered through the index finger stimulated a steady 40-hertz oscillation in the brains, as seen in magnetoencephalography. (The Globe and Mail)

Researcher Explains Obesity Research at Science Festival

April 26, 2016 - A talk at TechfestNW in Oregon presented the rationale for investigating deep brain stimulation of the hypothalamus as a therapeutic intervention in obesity. (Willamette Week)

News Feature Surveys the State of Research Into Minimally Conscious State

April 26, 2016 - An article about minimally conscious states mentions deep brain stimulation that helped to restore more conscious awareness to one patient. (Newsweek)

Authors Recount State of an International Registry of Tourette Syndrome Patients Who Have Received Deep Brain Stimulation

April 25, 2016 - A review details an international registry of patients with Tourette syndrome who received deep brain stimulation. The registry has 157 patients so far, from 10 countries. The review lists 16 studies published since 2007 that have more than four patients who received DBS as an investigational intervention in Tourette syndrome. (Frontiers in Neuroscience)

Review Summarizes Neuromodulation Studies in Heart Failure

April 25, 2016 - A review examines clinical experience with studies of spinal cord stimulation and vagus nerve stimulation in heart failure, as well as baroreceptor activation therapy. The review analyzes challenges of determining proper excitation parameters and/or stimulator duty cycles, among other issues. Despite challenges, the authors say much progress has been made in the past five years and that one day clinicians may use both devices and drugs to restore the proper sympathovagal balance in heart failure. They add that enrollment will begin soon in a large pivotal trial, BeAT-HF (Barostim Therapy for Heart Failure; NCT02627196). In it, 480 heart-failure patients will be randomized to receive optimal medical therapy with or without BAT. Results, however, will not be expected for several years. (Basic to Translational Science)

Study: Varying Stimulation Frequency May Aid Pain Control

April 22, 2016 - International Neuromodulation Society member Julie Pilitsis, MD, PhD and colleagues published results of a pain study involving 19 patients receiving deep brain stimulation. The authors found that low-frequency stimulation modulates thermal and mechanical detection more than high frequency stimulation, as determined through quantitative sensory testing. They postulate that low frequency stimulation may be an option to consider for patients with Parkinson's  disease whose pain is their predominant complaint. (Journal of Neurosurgery)

Modeling Indicates that Adjunctive Neurostimulation in Chronic Cluster Headache Would Improve Outcomes and Lower Treatment Costs

April 22, 2016 - Using data from a prospective, randomized, open-label study of non-invasive vagus nerve stimulation, researchers in Germany modeled the cost-effectiveness of this adjunctive treatment for chronic cluster headache compared to the current standard of care alone. Their analysis found that after one year, the combined treatment of vagus nerve stimulation plus standard care was projected to result in greater quality of life and lower healthcare expenditures in a German setting. (The Journal of Headache and Pain)

New Neurostimulation Company Receives up to $45 Million in Debt Financing

April 22, 2016 - Nuvectra's first disclosed financing is a $40 million loan and $5 million line of credit from Oxford Finance and Silicon Valley Bank. The newly spun-out neurostimulation company's overall market capitalization is about $90 million. (Fierce Medical Devices)

Company Acquires Startup's Neurostimulation Patents

April 22, 2016 - Nexeon MedSystems Inc. has acquired neuromodulation patents from NeuroTek Medical, Inc. related to electrode design and occipital nerve stimulation for migraine headache. NeuroTek created a device that delivers transcutaneous occipital nerve electrical stimulation as an investigational treatment for migraine pain. Nexeon anticipates using this intellectual property in its research into similar technology for cardiovascular disease, cognitive enhancement, and sepsis. (Biospace)

CE Mark Approved for Migraine Prevention Labeling

April 22, 2016 - The company eNeura has received an expanded CE mark for its single-pulse transcranial magnetic stimulation device to prevent migraine, as well as for acute treatment of migraine. (FDA News)

Article Recaps Researchers' Non-invasive Brain Stimulation Research

May 2016 - A news feature describes military-funded research that examines cognitive effects of non-invasive brain stimulation. The Insight project, begun in 2014 with $12.7 million from the U.S. Office of the Director of National Intelligence, combines physical fitness training, nutrition monitoring, and cognitive training sessions that include transcutaneous direct current stimulation in healthy volunteers. The 42-month project tracks adaptive reasoning in novel situations. (Smithsonian)

Cadaver Study Measured External Stimulation Entering the Skull

April 20, 2016 - Unpublished data presented at the annual meeting of the Cognitive Neuroscience Society earlier this month in New York City showed very little current entered a cadaver's skull which was fitted with transcutaneous electrodes to deliver alternating current, with most applied current shunted away by the skin. Regarding the findings, one researcher commented that transcutaneous brain stimulation in living subjects is not expected to deliver a stimulus strong enough to trigger neuron firing, but instead to make neurons more likely to fire or form new connections. In addition, he noted that living tissue conducts electricity differently. (Science)

Early-Onset Parkinson's Disease Patient in Scotland Appreciates Neuromodulation Therapy

April 20, 2016 - A retired teacher who belongs to the Glasgow Young Onset Parkinson’s Group discussed being able to receive deep brain stimulation (DBS). The article says that at a cost of around £70,000 to the National Health Service, only 10 to 12 operations are carried out a year. (Daily Record)

Survey Underscores Importance of Realistic Therapy Expectations in Parkinson's Disease Patients

April 20, 2016 - Survey results presented at the 2016 annual meeting of the American Academy of Neurology showed that Parkinson's disease patients whose pre-operation expectations were realistic had improved quality-of-life scores after their deep brain stimulation (DBS) surgery. The article states that "most patients continued to be satisfied with their decision to undergo DBS, would elect to undergo the procedure again if necessary, and would recommend the procedure to others. In addition, most participants reported that they would have preferred to undergo DBS earlier." (Neurology Advisor)

Research Team Unravels Dual Role of Brain Nucleus Neurons

April 20, 2016 - Preclinical experiments untangled a dual role for cholinergic neurons in the pedunculopontine nucleus by following projections to midbrain structures. The work indicates that to address gait issues in movement disorder, brain stimulation might target the axonal projections in the substantia nigra. For reward disorders, on the other hand, stimulation might target projections in the ventral tegmental area. (Medical Xpress)

FDA Ponders External Brain Stimulation Device Classifications

April 20, 2016 - The FDA is receiving comments on its proposal to reclassify cranial electrotherapy stimulator devices from Class III to Class II for insomnia and/or anxiety, while remaining Class III devices when intended for depression, requiring premarket approval. (Medical Device and Diagnostic Industry)

Transcranial Magnetic Stimulation System Maker Announces New European Patent

April 20, 2016 - Nexstim Plc announced the European Patent Office has issued a patent for the company's technology that displays where an electric field is generated on the brain during transcranial magnetic stimulation. (Globe Newswire)

Device Maker Cites Neuromodulation Revenue in Quarterly Earnings

April 20, 2016 - Neuromodulation sales at St. Jude Medical grew 8% in the first quarter and contributed to earnings and revenues the company said were above forecast. (Market Watch)

Paper Compares MRI Capabilities in Guiding Targeting of Deep Brain Stimulation

April 20, 2016 - Co-authors from the University of California, San Francisco compared deep brain stimulation (DBS) lead targeting during one year of operation using magnetic resonance imaging from ether a 3-tesla magnet (23 consecutive leads) or a 1.5-tesla magnet (26 consecutive leads). They concluded that accurate DBS lead targeting can be achieved with systems using either 1.5- or 3-tesla magnets, but a 3-tesla magnet provides better visualization of the target structures. (Stereotactic and Functional Neurosurgery)

Neurostimulation Spin-off Completes Private Financing Round

April 19, 2016 - A spinoff from the Swiss Federal Institute of Technology in Lausanne, G-Therapeutics, raised $41 million in a Series A round and debt. The company plans to use the proceeds on clinical trials for an implantable neurostimulation system to restore lower limb function spinal cord injury patients. (Fierce Medical Devices)

Non-invasive Stimulation Startup Raises Capital

April 18, 2016 - Helius Medical Technologies has raised $7.2 million in a Canadian short-form offering and a concurrent private placement in the U.S. The company is completing a clinical trial of non-invasive nerve stimulation for treatment of traumatic brain injury, in preparation for a request for FDA 510(k) clearance and an envisioned U.S. commercial launch. (Med City News)

Study: Non-invasive Vagus Nerve Stimulation Reduced Menstrual Migraine Frequency and Intensity

April 19, 2016 - An open-label study of 56 patients presented at the American Academy of Neurology meeting showed that non-invasive vagus nerve stimulation reduced the frequency of menstrual migraine by 35%, down to 4.7 episodes per cycle. The migraine episodes were also less intense, resulting in 38% less use of rescue/analgesic medication. Another study at the meeting provided evidence that the non-invasive stimulation is stimulating afferent vagus nerve fibers as expected. (Newswire)

Researchers Analyze Effect of Responsive Neurostimulation in Patients with Treatment-Resistant Epilepsy

April 18, 2016 - An analysis of 106 patients with medically intractable mesial temporal lobe epilepsy who participated in a clinical trial of responsive neurostimulation showed a median seizure reduction of 70%, according to data presented at the American Academy of Neurology meeting. (Neurology Advisor)

Spinal Cord Stimulation Leads Receive Pre-Market Approval

April 18, 2016 - Nevro Corp. announced FDA pre-market approval of its spinal cord stimulation leads for use with its high-frequency spinal cord stimulation device, which was FDA-approved in May 2015. (Mass Device)

Review Foresees Potentially Greater Role for Neuromodulation in Treatment-Resistant Depression

April 2016 - A review of electroconvulsive therapy, transcranial magnetic stimulation (TMS), and deep brain stimulation (DBS) in treatment-resistant depression concludes that as additional knowledge is developed about the best use of the latter two treatments, circumstances may allow TMS and DBS to become mainstream treatments for treatment-resistant depression in the next decade. (Healio Psychiatric Annals)

Researchers Say Non-invasive Brain Stimulation Improved Cognitive Reasoning on a Word-Analogy Test

April 14, 2016 - An article in Cerebral Cortex says research subjects performed better on a novel analogy-finding task after receiving high-definition tDCS-to the frontopolar cortex, an area whose activity was recently shown to predict changes in creative state. (Science Daily)

Journal Features Work of International Neuromodulation Society Members to Reanimate the Limb of a Quadraplegic

April 13, 2016 - The New York Times covered the publication in Nature of research including International Neuromodulation Society members Ali Rezai, MD, and Chad Bouton regarding their collaboration to use a motor-cortex implant and an electrode sleeve to reanimate the hand and arm of a man with quadriplegia. Nature published an associated news article. An article by the BBC includes a video of the young man using the device. Ohio State University issued a news release saying the patient is the first of up to five to participate in the clinical study using this "neural bypass" system, NeuroLife. Bouton was recognized for this work in 2015 as one of five winners of the inaugural INS biennial congress abstract competition. (New York Times)

Study: Deep Brain Stimulation Target Yielded Lasting Symptom Improvement in Parkinson's Patients

April 13, 2016 - Researchers in Mexico City report that unilateral deep brain stimulation to the preleminiscal radiations (Rapri) in patients who have Parkinson's disease in stages II - III induced significant improvement in contralateral symptoms in the extremities over 2 - 4 years of followup. Fourteen of the 19 patients had more than an 80% decrease in symptoms. The other five had symptom decreases of 33 - 79%. (Neuromodulation: Technology at the Neural Interface)

Advocacy Group's Survey in Ireland Shows Limited Access to Deep Brain Stimulation

April 13, 2016 - An article about a survey of 1,000 patients by the Parkinson’s Association of Ireland says that despite Parkinson's disease being on the rise, only 3% of patients have had access to deep brain stimulation. For the treatment, they must travel to England, which is difficult for patients whose condition limits their mobility. (Irish Times)

Man with Autism Recounts His Response as a Non-invasive Brain-Stimulation Subject

April 13, 2016 - In a "Science of Us" column, a writer interviews a man with autism about his experiences as a clinical research subject who had repetitive transcranial magnetic stimulation in an attempt to mitigate some of his symptoms that interfered with socialization. (New York Magazine)

Company Releases Dorsal Root Ganglion Neurostimulator in the U.S.

April 11, 2016 - St. Jude Medical announced the U.S. launch of its dorsal root ganglion (DRG) neurostimulator, following FDA approval in February. Providers are being trained in use of the device to treat people with chronic pain from complex regional pain syndrome I and II for whom traditional neurostimulation is not sufficiently effective. The company announced the first two procedures in a news release and said it has partnered with implanting chronic pain specialists who will conduct more than 100 procedures in 59 centers nationwide in the first month after launch. (MedGadget)

Authors Foresee Applying Laboratory Findings in Optogenetics to Deep Brain Stimulation Therapy

April 5, 2016 - Authors of a research review posit that optogenetics in animal models can identify neural circuits thought to contribute to behavioral disease, which then might be treated with deep brain stimulation. These possibly novel stimulation targets could be validated in the animal models. Then, the findings might be translated to humans. (Swiss Medical Weekly)

Small Clinical Trial Starts to Potentially Remedy Vision Loss with Optogenetics

March 18, 2016 - A woman in Texas with loss of vision from retinitis pigmentosa is the first participant in a small clinical trial to receive optogenetic therapy. The treatment introduces genes for light-sensing proteins to ganglion cells in her retina. The intent is to allow these cells to signal the presence of light, and thereby restore some ability to perceive light and shadow. Restoring some vision could help patients better perceive and navigate their environment. (MIT Technology Review)

Clinical Trial of Neurostimulation in Post-Amputation Pain Will Continue Following Interim Analysis of Early Results

April 7, 2016 - Neuros Medical, Inc. announced positive feedback from an analysis of interim results in the company's pivotal clinical study of high-frequency nerve stimulation for post-amputation pain. An independent data monitoring committee analyzed safety and efficacy outcomes for the first 20 patients in the study. Based on that analysis, the clinical trial will continue. The study seeks to ultimately enroll up to 130 patients at 15 institutions. (Business Wire)

Researchers Explore Potential Deep Brain Stimulation Target to Treat Pain

April 4, 2016 - The University of Texas at Arlington issued a news release about preclinical research into neurostimulation for pain that targets the ventral segmental area, a brain structure that plays roles in both the reward process and nociception. The researchers write in Experimental Brain Research that the stimulation may cause an analgesic effect and decrease nociceptive pain via descending modulatory pathways, possibly through connections to the brainstem and cerebral cortex. (Medial Xpress)

Public Body Says National Health Service Can Use Noninvasive Vagus Nerve Stimulation for Chronic Headache

April 1, 2016 - In a news release, electroCore LLC reports that the National Institute for Health and Care Excellence (NICE) has issued guidance on transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. NICE reviewed and summarized results of five clinical trials that documented the degree of benefit experienced by enrollees. The guidance to physicians encourages them to inform patients that evidence of efficacy is uncertain due to the extent and nature of the data published to date, but adds that further research is encouraged and "current evidence raises no major concerns". Based on the guidance issued by NICE, the intervention can now be used in the National Health Service. (PR Newswire)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.


How Has Neuromodulation Been Developed and Used?

Conventional medicine has typically had four modes of treating diseases or disorders: counseling or “talk therapy”; physical therapy involving manipulation and strengthening of muscles and range of motion; pharmaceuticals that act on a chemical level; and altering or augmenting tissue through surgery, injections, or filtering methods like dialysis. The growing field of neuromodulation is a new class of therapies that involves directly treating the nervous system itself, often through small implanted devices that target a specific area, to rebalance the activity of neural circuits and manage symptoms.

Progress has been spurred by advances in our understanding of the nervous system, as well as new technologies and clinical experience, enabling treatments to modify nerve cell activity in brain, spinal cord and periphery to restore function, minimize pain, and treat disease symptoms. Developed over the last 45 years, neuromodulation has grown rapidly into a family of therapies that applies stimulation or agents directly to the nervous system, often using small implanted medical devices that are powered in a similar fashion to a cardiac pacemaker. By delivering electrical or chemical stimulation, neuromodulation has increasingly been used to treat motor disorders such as Parkinson’s disease, refractory chronic pain ranging from neuropathy to cancer related pain to severe headaches, spasticity, epilepsy, and incontinence. It is also under study for conditions ranging from gastroparesis to medically refractory depression. Providers of such therapies include neurosurgeons, pain physician specialists and rehabilitation physicians. They may often work with other specialists such as neurologists, psychiatrists, psychologists, gastrointestinal or colorectal specialists, urologists, primary care physicians, and physical therapists to achieve best outcomes.

Learn More . . .

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Resources and Research pages. Neuromodulator trials address symptom control through nerve stimulation in such condition categories as:


If you are not a medical professional
and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation - the alteration of nerve activity through the delivery of electrical stimulation or chemical agents to targeted sites of the body. Founded in 1989 and based in San Francisco, CA, the INS educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites.

See patient information


Now indexed in MEDLINE!

journal cover

Neuromodulation: Technology at the Neural Interface
contains articles of the highest scientific caliber. The journal's sole purpose is to advance the basic and clinical science of the field of neuromodulation. In eight issues a year, it publishes scientific works, scientific reviews, and abstracts of papers accepted for review at national and international congresses.

Neuromodulation is now indexed in Index Medicus, MEDLINE and Pubmed!

Click here to submit a manuscript.


Unique Member Benefit

brain concept

Members may log in and visit the members-only section’s Global Discussion Forum to participate;
watch for updates on our
Events page
and in our journal


Site Index

Bookmark and Share



Members may now join:
Google Groups

 
back to top
Last Updated on Thursday, May 26, 2016 08:51 AM
 
powered by MemberClicks